PKMYT1 and cancer: Among them, RP-6306 developed by Repare Therapeutics is the first orally bioavailable and selective PKMYT1 inhibitor that has shown robust antitumor activity in preclinical models and is currently under evaluation in phase II clinical trials for patients with advanced cancer (Szychowski et al., 2022).